Effects of Jetepar (glucometamine, glucodiamine and nicotinamide ascorbate) on Isoniazid Induced Hepatotoxicity in Rabbits
Background: Isoniazid (INH), first line drug for antitubercular treatment, induces hepatic necrosis in some of human beings in normal doses and in experimental animals in toxic doses. Reactive toxic metabolites of INH are released which disrupt hepatocellular membrane and cause necrosis. So there is a need to find some hepatoprotective and antioxidant agent. Jetepar, combination of glucometamine, glucodiamine and nictonamide ascorbate is non-toxic to liver and used for viral hepatitis. Purpose of our research was to observe the effects of jetepar against INH-induced hepatotoxicity in rabbit model.
Methods: Study was conducted on oryctolagus cuniculus rabbits (1-1.5 kg) of either sex for the period of 11 days. Animals were divided in five groups at random with 6 animals in each group. In group I normal liver function tests were recorded without any drug. In group II isoniazid (50mg/kg /day i.p) was administered. In Group III effects of jetepar (3cc/kg /day i.m) were observed. In group IV and V combined effects of isoniazid and jetepar were observed with two different doses. In liver function tests serum bilirubin, ALT and AST were performed on 12th day. Animals were sacrificed on 12th day for observing histopathological changes in liver.
Results: In group II, bilirubin level increased significantly. Histological picture revealed ballooning degeneration, portal inflammation and necrosis of hepatocytes which are signs of acute inflammation. In group III, rabbits gained weight and liver architecture remained intact. In group IV and V, there was significant improvement in liver architecture when compared with group II. So it can be concluded that INH induced biochemical and histopathological changes are significantly antagonized by concurrent administration of jetepar for 11days.
Key Words: INH-induced hepatotoxicity, liver function tests, liver histology.
How to Cite
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments email@example.com